Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - GEN
LB  - 1.
AU  - National Institute of Health and Clinical Excellence (NICE)
TI  - Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer’s disease (amended)
CY  - London
PB  - NICE
PY  - 2009
ER  - 
TY  - BOOK
LB  - 2.
AU  - Loveman, E
AU  - Green, C
AU  - Kirby, J
AU  - Takeda, A
AU  - Picot, J
AU  - Payne, E
TI  - The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease
CY  - Southampton
PB  - University of Southampton
PY  - 2004
ER  - 
TY  - GEN
LB  - 3.
AU  - American Psychiatric Association
TI  - Diagnostic and Statistical Manual of Mental Disorder
ET  - 4th
CY  - Washington, DC
PB  - American Psychiatric Association
PY  - 2000
ER  - 
TY  - GEN
LB  - 4.
AU  - World Health Organization (WHO)
TI  - The ICD 10 classification of mental and Behavioural Disorders: diagnostic criteria for research
CY  - Geneva
PB  - WHO
PY  - 1993
ER  - 
TY  - GEN
LB  - 5.
AU  - National Collaborating Centre for Mental Health
TI  - Dementia: a NICE-SCIE Guideline on Supporting People with Dementia and their Carers in Health and Social Care
CY  - National Clinical Practice Guideline. Leicester
PB  - The British Psychological Society and Gaskell
PY  - 2007
ER  - 
TY  - JOUR
LB  - 6.
AU  - McKhann, G
AU  - Drachman, D
AU  - Folstein, M
AU  - Katzman, R
AU  - Price, D
AU  - Stadlan, EM
TI  - Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease
J2  - Neurology
PY  - 1984
VL  - 34
SP  - 939
EP  - 944
ER  - 
TY  - BOOK
LB  - 7.
AU  - Warrell, DA
AU  - Cox, TM
AU  - Firth, JD
TI  - Oxford textbook of medicine
ET  - 4th
CY  - Oxford
PB  - Oxford University Press
PY  - 2003
ER  - 
TY  - RPRT
LB  - 8.
AU  - Knapp, M
AU  - Prince, M
AU  - Albanese, E
AU  - Banerjee, S
AU  - Dhanasiri, S
AU  - Fernandez, J
TI  - Dementia UK: the full report
CY  - London
PB  - Alzheimer’s Society
PY  - 2007
ER  - 
TY  - GEN
LB  - 9.
AU  - National Audit Office
TI  - Improving services and support for people with dementia
CY  - London
PB  - The Stationary Office
PY  - 2007
ER  - 
TY  - BOOK
LB  - 10.
AU  - Luengo-Fernandez, R
AU  - Leal, J
AU  - Gray, A
TI  - Dementia 2010: The economic burden of dementia and associated research funding in the United Kingdom
CY  - Cambridge
PB  - Alzheimer’s Research Trust
PY  - 2010
ER  - 
TY  - JOUR
LB  - 11.
AU  - Yip, AG
AU  - Brayne, C
AU  - Matthews, FE
TI  - Risk factors for incident dementia in England and Wales: The Medical Research Council Cognitive Function and Ageing Study. A population-based nested case–control study
J2  - Age Ageing
PY  - 2006
VL  - 35
SP  - 154
EP  - 160
ER  - 
TY  - JOUR
LB  - 12.
AU  - Matthews, F
AU  - Brayne, C
TI  - The incidence of dementia in England and Wales: findings from the five identical sites of the MRC CFA Study
J2  - PLoS Med
PY  - 2005
VL  - 2
SP  - e193
ER  - 
TY  - JOUR
LB  - 13.
AU  - Alzheimer’s Association
TI  - Alzheimer’s disease facts and figures
J2  - Alzheimers Dement
PY  - 2009
VL  - 5
SP  - 234
EP  - 270
ER  - 
TY  - JOUR
LB  - 14.
AU  - Hardy, J
TI  - New insights into the genetics of Alzheimer’s disease
J2  - Ann Med
PY  - 1996
VL  - 28
SP  - 255
EP  - 258
ER  - 
TY  - JOUR
LB  - 15.
AU  - Cruts, M
AU  - van Duijn, CM
AU  - Backhovens, H
AU  - Van den, BM
AU  - Wehnert, A
AU  - Serneels, S
TI  - Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease
J2  - Hum Mol Genet
PY  - 1998
VL  - 7
SP  - 43
EP  - 51
ER  - 
TY  - JOUR
LB  - 16.
AU  - Schellenberg, G
AU  - Anderson, L
AU  - O’dahl, S
TI  - APP717, APP693 and PRIP gene mutations are rare in Alzheimer’s disease
J2  - Am J Hum Genet
PY  - 1991
VL  - 49
SP  - 511
EP  - 517
ER  - 
TY  - JOUR
LB  - 17.
AU  - Takashi, ASAD
TI  - Prevention of Alzheimer’s disease: putative nutritive factors
J2  - Psychogeriatrics
PY  - 2007
VL  - 7
SP  - 125
EP  - 131
ER  - 
TY  - JOUR
LB  - 18.
AU  - Rolland, YM
AU  - Pillard, FM
AU  - Klapouszczak, AM
AU  - Reynish, EM
AU  - Thomas, DM
AU  - Andrieu, SM
TI  - Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial
J2  - J Am Geriatr Soc
PY  - 2007
VL  - 55
SP  - 158
EP  - 165
ER  - 
TY  - JOUR
LB  - 19.
AU  - Fratiglioni, L
AU  - Paillard-Borg, S
AU  - Winblad, B
TI  - An active and socially integrated lifestyle in late life might protect against dementia
J2  - Lancet Neurol
PY  - 2004
VL  - 3
SP  - 343
EP  - 353
ER  - 
TY  - JOUR
LB  - 20.
AU  - Fitzpatrick, AL
AU  - Kuller, LH
AU  - Lopez, OL
AU  - Kawas, CH
AU  - Jagust, W
TI  - Survival following dementia onset: Alzheimer’s disease and vascular dementia
J2  - J Neurol Sci
PY  - 2005
VL  - 229
SP  - 43
EP  - 49
ER  - 
TY  - JOUR
LB  - 21.
AU  - Backman, L
AU  - Jones, S
AU  - Berger, AK
AU  - Laukka, EJ
AU  - Small, BJ
TI  - Multiple cognitive deficits during the transition to Alzheimer’s disease
J2  - J Intern Med
PY  - 2004
VL  - 256
SP  - 195
EP  - 204
ER  - 
TY  - JOUR
LB  - 22.
AU  - Arnaiz, E
AU  - Almkvist, O
TI  - Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease
J2  - Acta Neurol Scand
PY  - 2003
SP  - 34
EP  - 41
ER  - 
TY  - JOUR
LB  - 23.
AU  - Ritchie, K
AU  - Lovestone, S
TI  - The dementias
J2  - Lancet
PY  - 2002
VL  - 360
SP  - 1759
EP  - 1766
ER  - 
TY  - JOUR
LB  - 24.
AU  - Brodaty, H
AU  - Hadzi-Pavlovic, D
TI  - Psychosocial effects on carers of living with persons with dementia
J2  - Aust N Z J Psychiatry
PY  - 1990
VL  - 24
SP  - 351
EP  - 361
ER  - 
TY  - JOUR
LB  - 25.
AU  - Carlesimo, GA
AU  - Oscar-Berman, M
TI  - Memory deficits in Alzheimer’s patients: a comprehensive review
J2  - Neuropsychol Rev
PY  - 1992
VL  - 3
SP  - 119
EP  - 169
ER  - 
TY  - JOUR
LB  - 26.
AU  - Frank, EM
TI  - Effect of Alzheimer’s disease on communication function
J2  - J S C Med Assoc
PY  - 1994
VL  - 90
SP  - 417
EP  - 423
ER  - 
TY  - JOUR
LB  - 27.
AU  - Wimo, A
AU  - Gustafsson, L
AU  - Mattson, B
TI  - Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders
J2  - Scand J Prim Health Care
PY  - 1992
VL  - 10
SP  - 185
EP  - 191
ER  - 
TY  - JOUR
LB  - 28.
AU  - Drachman, DA
AU  - O’Donnell, BF
AU  - Lew, RA
AU  - Swearer, JM
TI  - The prognosis in Alzheimer’s disease. ‘How far’ rather than ‘how fast’ best predicts the course
J2  - Arch Neurol
PY  - 1990
VL  - 47
SP  - 851
EP  - 856
ER  - 
TY  - JOUR
LB  - 29.
AU  - Brodaty, H
AU  - McGilchrist, C
AU  - Harris, L
AU  - Peters, KE
TI  - Time until institutionalization and death in patients with dementia: role of caregiver training and risk factors
J2  - Arch Neurol
PY  - 1993
VL  - 50
SP  - 643
EP  - 650
ER  - 
TY  - JOUR
LB  - 30.
AU  - Thompson, C
AU  - Spilsbury, K
AU  - Hall, J
AU  - Birks, Y
AU  - Barnes, C
AU  - Adamson, J
TI  - Systematic review of information and support interventions for caregivers of people with dementia
J2  - BMC Geriatrics
PY  - 2007
VL  - 7
SP  - 18
ER  - 
TY  - JOUR
LB  - 31.
AU  - Aguglia, E
AU  - Onor, 
TI  - Stress in the caregivers of Alzheimer’s patients: An experimental investigation in Italy
J2  - Am J Alzheimers Dis Other Demen
PY  - 2004
VL  - 19
SP  - 248
EP  - 252
ER  - 
TY  - JOUR
LB  - 32.
AU  - Holland, JM
AU  - Currier, JM
AU  - Gallagher-Thompson, D
TI  - Outcomes From the Resources for Enhancing Alzheimer’s Caregiver Health (REACH) Program for Bereaved Caregivers
J2  - Psychol Aging
PY  - 2009
VL  - 24
SP  - 190
EP  - 202
ER  - 
TY  - JOUR
LB  - 33.
AU  - Garity, JE
TI  - Caring for a Family Member with Alzheimer’s Disease: Coping with Caregiver Burden Post-Nursing Home Placement
J2  - J Gerontol Nurs
PY  - 2006
VL  - 32
SP  - 39
EP  - 48
ER  - 
TY  - JOUR
LB  - 34.
AU  - Vitaliano, PP
AU  - Echeverria, D
AU  - Yi, J
AU  - Phillips, PEM
AU  - Young, H
AU  - Siegler, IC
TI  - Psychophysiological Mediators of Caregiver Stress and Differential Cognitive Decline
J2  - Psychol Aging
PY  - 2005
VL  - 20
SP  - 402
EP  - 411
ER  - 
TY  - JOUR
LB  - 35.
AU  - Bianchetti, A
AU  - Scuratti, A
AU  - Zanetti, O
AU  - Binetti, G
AU  - Frisoni, GB
AU  - Magni, E
TI  - Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit
J2  - Dementia
PY  - 1995
VL  - 6
SP  - 108
EP  - 112
ER  - 
TY  - JOUR
LB  - 36.
AU  - Donaldson, C
AU  - Tarrier, N
AU  - Burns, A
TI  - The impact of the symptoms of dementia on caregivers
J2  - Br J Psychiatry
PY  - 1997
VL  - 170
SP  - 62
EP  - 68
ER  - 
TY  - JOUR
LB  - 37.
AU  - Adams, KB
AU  - Sanders, SA
TI  - Alzheimer’s caregiver differences in experience of loss, grief reactions and depressive symptoms across stage of disease: a mixed-method analysis
J2  - Dementia
PY  - 2004
VL  - 3
SP  - 195
EP  - 210
ER  - 
TY  - JOUR
LB  - 38.
AU  - Schneider, J
AU  - Murray, J
AU  - Banerjee, S
AU  - Mann, A
TI  - EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer’s disease: I--Factors associated with carer burden
J2  - Int J Geriatr Psychiatry
PY  - 1999
VL  - 14
SP  - 651
EP  - 661
ER  - 
TY  - JOUR
LB  - 39.
AU  - Mittelman, MS
AU  - Haley, WE
AU  - Clay, OJM
AU  - Roth, DLP
TI  - Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease
J2  - Neurology
PY  - 2006
VL  - 67
SP  - 1592
EP  - 1599
ER  - 
TY  - JOUR
LB  - 40.
AU  - Banerjee, S
AU  - Murray, J
AU  - Foley, B
AU  - Atkins, L
AU  - Schneider, J
AU  - Mann, A
TI  - Predictors of institutionalisation in people with dementia
J2  - J Neurol Neurosurg Psychiatry
PY  - 2003
VL  - 74
SP  - 1315
EP  - 1316
ER  - 
TY  - JOUR
LB  - 41.
AU  - de Vugt, ME
AU  - Stevens, F
AU  - Aalten, P
AU  - Lousberg, R
AU  - Jaspers, N
AU  - Verhey, FRJ
TI  - A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia
J2  - Int Psychogeriatr
PY  - 2005
VL  - 17
SP  - 577
EP  - 589
ER  - 
TY  - BOOK
LB  - 42.
AU  - Wolfson, C
AU  - Moride, Y
AU  - Perrault, A
TI  - Drug treatments for Alzheimer’s disease. II: a review of outcome measures in clinical trials
CY  - Ottawa, ON
PB  - Canadian Coordinating Office for Health Technology Assessment
PY  - 2000
ER  - 
TY  - JOUR
LB  - 43.
AU  - Wolfson, C
AU  - Oremus, M
AU  - Shukla, V
AU  - Momoli, F
AU  - Demers, L
AU  - Perrault, A
TI  - Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness
J2  - Clin Ther
PY  - 2002
VL  - 24
SP  - 862
EP  - 886
ER  - 
TY  - JOUR
LB  - 44.
AU  - Folstein, MF
AU  - Folstein, SE
AU  - McHugh, PR
TI  - ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician
J2  - J Psychiatry Res
PY  - 1975
VL  - 12
SP  - 189
EP  - 198
ER  - 
TY  - JOUR
LB  - 45.
AU  - Mohs, RC
AU  - Rosen, WG
AU  - Davis, KL
TI  - The Alzheimer’s disease assessment scale: an instrument for assessing treatment efficacy
J2  - Psychopharmacol Bull
PY  - 1983
VL  - 19
SP  - 448
EP  - 450
ER  - 
TY  - JOUR
LB  - 46.
AU  - Roselli, F
AU  - Tartaglione, B
AU  - Federico, F
AU  - Lepore, V
AU  - Defazio, G
AU  - Livrea, P
TI  - Rate of MMSE score change in Alzheimer’s disease: influence of education and vascular risk factors
J2  - Clin Neurol Neurosurg
PY  - 2009
VL  - 111
SP  - 327
EP  - 330
ER  - 
TY  - JOUR
LB  - 47.
AU  - Tombaugh, TN
TI  - Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS
J2  - Arch Clin Neuropsychol
PY  - 2005
VL  - 20
SP  - 485
EP  - 503
ER  - 
TY  - JOUR
LB  - 48.
AU  - Irizarry, MC
AU  - Webb, DJ
AU  - Bains, C
AU  - Barrett, SJ
AU  - Lai, RY
AU  - Laroche, JP
TI  - Predictors of placebo group decline in the Alzheimer’s disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer’s disease
J2  - J Alzheimers Dis
PY  - 2008
VL  - 14
SP  - 301
EP  - 311
ER  - 
TY  - JOUR
LB  - 49.
AU  - Cummings, JL
AU  - Mega, M
AU  - Gray, K
AU  - Rosenberg-Thompson, S
AU  - Carusi, DA
AU  - Gornbein, J
TI  - The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia
J2  - Neurology
PY  - 1994
VL  - 44
SP  - 2308
EP  - 2314
ER  - 
TY  - JOUR
LB  - 50.
AU  - Hughes, CP
AU  - Berg, L
AU  - Danziger, WL
AU  - Coben, LA
AU  - Martin, RL
TI  - A new clinical scale for the staging of dementia
J2  - Br J Psychiatry
PY  - 1982
VL  - 140
SP  - 566
EP  - 572
ER  - 
TY  - JOUR
LB  - 51.
AU  - Boothby, H
AU  - Mann, AH
AU  - Barker, A
TI  - Factors determining inter-rater agreement with rating global change in dementia: CIBIC-plus
J2  - Int J Geriatr Psychiatry
PY  - 1995
VL  - 10
SP  - 1037
EP  - 1045
ER  - 
TY  - JOUR
LB  - 52.
AU  - Claus, JJ
AU  - Teunisse, S
AU  - Walstra, GJM
AU  - van Gool, WA
TI  - Determinants of Global Clinical Change Assessment in Patients with Early Alzheimer’s Disease
J2  - Dement Geriatr Cogn Discord
PY  - 1998
VL  - 9
SP  - 157
EP  - 163
ER  - 
TY  - JOUR
LB  - 53.
AU  - Gauthier, S
AU  - Bodick, N
AU  - Erzigkeit, E
AU  - Feldman, H
AU  - Geldmacher, DS
AU  - Huff, J
TI  - Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
J2  - Alzheimer Dis Assoc Disord
PY  - 1997
VL  - 11
IS  - Suppl. 3
SP  - 6
EP  - 7
ER  - 
TY  - CHAP
LB  - 54.
AU  - Nygard, L
TI  - Assessing ADL/IADL in persons with dementia
A2  - Wimo, A
A2  - Jonnson, B
A2  - Karlsson, G
A2  - Winblad, B
T2  - Health economics of dementia
CY  - New York, NY
PB  - John Wiley and Sons
PY  - 1998
SP  - 371
EP  - 388
ER  - 
TY  - BOOK
LB  - 55.
AU  - McDowell, I
AU  - Newell, C
TI  - Measuring health: a guide to rating scales and questionnaires
ET  - 2nd
CY  - New York, NY
PB  - Oxford University Press
PY  - 1996
ER  - 
TY  - JOUR
LB  - 56.
AU  - Smith, SC
AU  - Lampling, DL
AU  - Banerjee, S
AU  - Harwood, R
AU  - Foley, B
AU  - Smith, P
TI  - Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology
J2  - Health Technol Assess
PY  - 2005
VL  - 9
IS  - 10
ER  - 
TY  - JOUR
LB  - 57.
AU  - Blau, TH
TI  - Quality of life, social indicators and criteria of change
J2  - Prof Psychol
PY  - 1977
VL  - 8
SP  - 464
EP  - 473
ER  - 
TY  - GEN
LB  - 58.
AU  - Department of Health
TI  - Living well with dementia: a national dementia strategy
CY  - London
PB  - Department of Health
PY  - 2009
ER  - 
TY  - BOOK
LB  - 59.
AU  - Pickard, L
AU  - Wittenburg, R
AU  - Commas-Herrera, A
AU  - Davis, B
AU  - Darton, R
TI  - Community care for frail older people: analysis using the 1998/99 General Household Survey. Quality in later life: rights, rhetoric and reality
CY  - Stirling
PB  - University of Stirling
PY  - 2001
ER  - 
TY  - GEN
LB  - 60.
AU  - Audit Commission
TI  - Support for Carers of Older People
CY  - London
PB  - Audit Commission
PY  - 2004
ER  - 
TY  - JOUR
LB  - 61.
AU  - Comas-Herrera, A
AU  - Wittenberg, R
AU  - Pickard, L
AU  - Knapp, M
TI  - Cognitive impairment in older people: future demand for long-term care services and the associated costs
J2  - Int J Geriatr Psychiat
PY  - 2007
VL  - 22
SP  - 1037
EP  - 1045
ER  - 
TY  - GEN
LB  - 62.
AU  - National Assembly for Wales
TI  - Caring about Carers: A Strategy for Carers in Wales. Implementation plan
CY  - Cardiff
PB  - National Assembly for Wales
PY  - 2000
ER  - 
TY  - GEN
LB  - 63.
AU  - Secretary of State for Health
TI  - The NHS Plan. Cm 4818
CY  - London
PB  - The Stationery Office
PY  - 2000
ER  - 
TY  - JOUR
LB  - 64.
AU  - Morris, RG
AU  - Morris, LW
AU  - Britton, PG
TI  - Factors affecting the emotional wellbeing of the caregivers of dementia sufferers
J2  - Br J Psychiatry
PY  - 1988
VL  - 153
SP  - 147
EP  - 156
ER  - 
TY  - JOUR
LB  - 65.
AU  - Livingston, G
AU  - Manela, M
AU  - Katona, C
TI  - Depression and other psychiatric morbidity in carers of elderly people living at home
J2  - BMJ
PY  - 1996
VL  - 312
SP  - 153
EP  - 156
ER  - 
TY  - JOUR
LB  - 66.
AU  - Medical Research Council
TI  - Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study
J2  - Psychol Med
PY  - 1998
VL  - 28
SP  - 319
EP  - 335
ER  - 
TY  - CHAP
LB  - 67.
AU  - Evandrou, M
TI  - Employment and care, paid and unpaid work: the socioeconomic position of informal carers in Britain
A2  - Phillips, J
T2  - Working carers
CY  - Aldershot
PB  - Avebury
PY  - 1995
ER  - 
TY  - GEN
LB  - 68.
AU  - Royal College of General Practitioners
TI  - Information Sheet. Profile of General Practitioners
PY  - 2006
ER  - 
TY  - GEN
LB  - 69.
AU  - Royal College of Psychiatrists
TI  - Who cares wins. Improving the outcome for older people admitted to the general hospital: guidelines for the development of Liaison Mental Health Services for older people
PY  - 2005
ER  - 
TY  - RPRT
LB  - 70.
AU  - Barnes, D
AU  - Lombardo, C
TI  - A profile of older people’s mental health services: Report of Service Mapping 2006
CY  - Durham
PB  - Durham University
PY  - 2006
ER  - 
TY  - GEN
LB  - 71.
AU  - Membership Office
TI  - Royal College of Psychiatrists
PY  - 2007
ER  - 
TY  - JOUR
LB  - 72.
AU  - Roth, M
AU  - Tym, E
AU  - Mountjoy, CQ
AU  - Huppert, FA
AU  - Hendrie, H
AU  - Verma, S
AU  - CAMDEX
TI  - A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
J2  - Br J Psychiatry
PY  - 1986
VL  - 149
SP  - 698
EP  - 709
ER  - 
TY  - GEN
LB  - 73.
AU  - Department of Health, Care Services Improvement Partnership
TI  - Everybody’s Business. Integrated mental health service for older adults: a service development guide
CY  - London
PB  - Department of Health
PY  - 2005
ER  - 
TY  - GEN
LB  - 74.
AU  - Audit Commission
TI  - Forget-me-not 2002: mental health services for older people
PY  - 2002
CY  - London
PB  - Audit Commission
ER  - 
TY  - GEN
LB  - 75.
AU  - Department of Health
TI  - National Service Framework for Older People
CY  - London
PB  - Department of Health
PY  - 2001
ER  - 
TY  - GEN
LB  - 76.
AU  - Audit Commission
TI  - Forget-me-not: mental health services for older people
CY  - London
PB  - The Audit Commission
PY  - 2000
ER  - 
TY  - GEN
LB  - 77.
AU  - NHS Centre for Reviews and Dissemination
TI  - Systematic Reviews: CRD’s guidance for undertaking reviews in healthcare
CY  - York
PB  - CRD University of York
PY  - 2009
ER  - 
TY  - JOUR
LB  - 78.
AU  - Moher, D
AU  - Liberati, A
AU  - Tetzlaff, J
AU  - Altman, DG
AU  - for the PRISMA Group
TI  - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
J2  - BMJ
PY  - 2009
VL  - 339
SP  - b2535
ER  - 
TY  - JOUR
LB  - 79.
AU  - Moher, D
AU  - Cook, DJ
AU  - Eastwood, S
AU  - Olkin, I
AU  - Rennie, D
AU  - Stroup, DF
TI  - Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
J2  - Lancet
PY  - 1999
VL  - 354
SP  - 1896
EP  - 1900
ER  - 
TY  - JOUR
LB  - 80.
AU  - DerSimonian, R
AU  - Laird, N
TI  - Meta-analysis in clinical trials
J2  - Control Clin Trials
PY  - 1986
VL  - 7
SP  - 177
EP  - 188
ER  - 
TY  - JOUR
LB  - 81.
AU  - Cochran, WG
TI  - The Combination of Estimates from Different Experiments
J2  - Biometrics
PY  - 1954
VL  - 10
SP  - 101
EP  - 129
ER  - 
TY  - JOUR
LB  - 82.
AU  - Higgins, JPT
AU  - Thompson, SG
TI  - Quantifying heterogeneity in a meta-analysis
J2  - Stat Med
PY  - 2002
VL  - 21
SP  - 1539
EP  - 1558
ER  - 
TY  - JOUR
LB  - 83.
AU  - Higgins, JPT
AU  - Thompson, SG
AU  - Deeks, JJ
AU  - Altman, DG
TI  - Measuring inconsistency in meta-analyses
J2  - BMJ
PY  - 2003
VL  - 327
SP  - 557
EP  - 560
ER  - 
TY  - JOUR
LB  - 84.
AU  - Egger, M
AU  - Smith, GD
AU  - Schneider, M
AU  - Minder, C
TI  - Bias in meta-analysis detected by a simple, graphical test
J2  - BMJ
PY  - 1997
VL  - 315
SP  - 629
EP  - 634
ER  - 
TY  - GEN
LB  - 85.
AU  - The Cochrane Collaboration
TI  - Cochrane Handbook for Systematic Reviews of Interventions
CY  - London
PB  - Cochrane Collaboration
PY  - 2009
ER  - 
TY  - JOUR
LB  - 86.
AU  - Molnar, FJ
AU  - Hutton, B
AU  - Fergusson, D
TI  - Does analysis using ‘last observation carried forward’ introduce bias in dementia research?
J2  - Can Med Assoc J
PY  - 2008
VL  - 179
SP  - 751
EP  - 753
ER  - 
TY  - JOUR
LB  - 87.
AU  - Thompson, SG
AU  - Sharp, SJ
TI  - Explaining heterogeneity in meta-analysis: a comparison of methods
J2  - Stat Med
PY  - 1999
VL  - 18
SP  - 2693
EP  - 2708
ER  - 
TY  - BOOK
LB  - 88.
AU  - Egger, M
AU  - Smith, GD
AU  - Altman, DG
TI  - Systematic reviews in health care: meta-analysis in context
ET  - 2nd
CY  - London
PB  - BMJ Books
PY  - 2001
ER  - 
TY  - JOUR
LB  - 89.
AU  - Ades, AE
TI  - A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence
J2  - Stat Med
PY  - 2003
VL  - 22
SP  - 2995
EP  - 3016
ER  - 
TY  - JOUR
LB  - 90.
AU  - Caldwell, DM
AU  - Ades, AE
AU  - Higgins, JP
TI  - Simultaneous comparison of multiple treatments: combining direct and indirect evidence
J2  - BMJ
PY  - 2005
VL  - 331
SP  - 897
EP  - 900
ER  - 
TY  - JOUR
LB  - 91.
AU  - Lu, G
AU  - Ades, AE
TI  - Combination of direct and indirect evidence in mixed treatment comparisons
J2  - Stat Med
PY  - 2004
VL  - 23
SP  - 3105
EP  - 3124
ER  - 
TY  - JOUR
LB  - 92.
AU  - Higgins, JP
AU  - Whitehead, A
TI  - Borrowing strength from external trials in a meta-analysis
J2  - Stat Med
PY  - 1996
VL  - 15
SP  - 2733
EP  - 2749
ER  - 
TY  - JOUR
LB  - 93.
AU  - Rogers, SL
AU  - Doody, RS
AU  - Mohs, RC
AU  - Friedhoff, LT
TI  - Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study
J2  - Arch Int Med
PY  - 1998
VL  - 158
SP  - 1021
ER  - 
TY  - JOUR
LB  - 94.
AU  - Birks, J
AU  - Evans, JG
AU  - Iakovidou, V
AU  - Tsolaki, M
TI  - Rivastigmine for Alzheimer’s disease
J2  - Cochrane Database Syst Rev
PY  - 2009
VL  - 2
ER  - 
TY  - GEN
LB  - 95.
AU  - Institute for Quality and Efficiency in Health Care (IQWiG)
TI  - Cholinesterase inhibitors in Alzheimer’s disease. Cologne: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
PY  - 2007
ER  - 
TY  - JOUR
LB  - 96.
AU  - Brodaty, H
AU  - Corey-Bloom, J
AU  - Potocnik, FCV
AU  - Truyen, L
AU  - Gold, M
AU  - Damaraju, CRV
TI  - Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease
J2  - Dement Geriatr Cogn Disord
PY  - 2005
VL  - 20
SP  - 120
EP  - 132
ER  - 
TY  - JOUR
LB  - 97.
AU  - Rockwood, K
AU  - Fay, S
AU  - Song, X
AU  - MacKnight, C
AU  - Gorman, M
AU  - Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators
TI  - Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial
J2  - CMAJ
PY  - 2006
VL  - 174
SP  - 1099
EP  - 1105
ER  - 
TY  - JOUR
LB  - 98.
AU  - Bullock, R
TI  - Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings
J2  - Curr Med Res Opin
PY  - 2005
VL  - 21
SP  - 1
EP  - 10
ER  - 
TY  - JOUR
LB  - 99.
AU  - Cumbo, E
TI  - Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer’s disease: 18-month, randomized, open-label trial
J2  - Prim Care Community Psychiatr
PY  - 2005
VL  - 10
SP  - 95
EP  - 102
ER  - 
TY  - JOUR
LB  - 100.
AU  - Raina, P
AU  - Santaguida, P
AU  - Ismaila, A
AU  - Patterson, C
AU  - Cowan, D
AU  - Levine, M
TI  - Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline
J2  - Ann Int Med
PY  - 2008
VL  - 148
SP  - 379
EP  - 397
ER  - 
TY  - JOUR
LB  - 101.
AU  - Bullock, R
AU  - Erkinjuntti, T
AU  - Lilienfeld, S
TI  - Management of patients with Alzheimer’s disease plus cerebrovascular disease: 12-Month treatment with galantamine
J2  - Dement Geriatr Cogn Disord
PY  - 2004
VL  - 17
SP  - 29
EP  - 34
ER  - 
TY  - JOUR
LB  - 102.
AU  - Hansen, RA
AU  - Gartlehner, G
AU  - Lohr, KN
AU  - Kaufer, DI
AU  - Hansen, RA
AU  - Gartlehner, G
TI  - Functional outcomes of drug treatment in Alzheimer’s disease: a systematic review and meta-analysis
J2  - Drugs Aging
PY  - 2007
VL  - 24
SP  - 155
EP  - 167
ER  - 
TY  - JOUR
LB  - 103.
AU  - Bentham, P
AU  - Gray, R
AU  - Raftery, J
AU  - Hills, R
AU  - Sellwood, E
AU  - Courtney, C
TI  - Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial
J2  - Lancet
PY  - 2004
VL  - 363
SP  - 2105
EP  - 2115
ER  - 
TY  - JOUR
LB  - 104.
AU  - Burns, A
AU  - Rossor, M
AU  - Hecker, J
AU  - Gauthier, S
AU  - Petit, H
AU  - Moeller, HJ
TI  - The effects of donepezil in Alzheimer’s disease: results from a multinational trial
J2  - Dement Geriatr Cogn Disord
PY  - 1999
VL  - 10
SP  - 237
EP  - 244
ER  - 
TY  - JOUR
LB  - 105.
AU  - Gauthier, S
AU  - Feldman, H
AU  - Hecker, J
AU  - Vellas, B
AU  - Emir, B
AU  - Subbiah, P
TI  - Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease
J2  - Curr Med Res Opin
PY  - 2002
VL  - 18
SP  - 347
ER  - 
TY  - JOUR
LB  - 106.
AU  - Greenberg, SM
AU  - Tennis, MK
AU  - Brown, LB
AU  - Gomez-Isla, T
AU  - Hayden, DL
AU  - Schoenfeld, DA
TI  - Donepezil therapy in clinical practice: a randomized crossover study
J2  - Arch Neurol
PY  - 2000
VL  - 57
SP  - 94
EP  - 99
ER  - 
TY  - JOUR
LB  - 107.
AU  - Holmes, C
AU  - Wilkinson, D
AU  - Dean, C
AU  - Vethanayagam, S
AU  - Olivieri, S
AU  - Langley, A
TI  - The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
J2  - Neurology
PY  - 2004
VL  - 63
SP  - 214
EP  - 219
ER  - 
TY  - JOUR
LB  - 108.
AU  - Homma, A
AU  - Takeda, M
AU  - Imai, Y
AU  - Udaka, F
AU  - Hasegawa, K
AU  - Kameyama, M
TI  - Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group
J2  - Dement Geriatr Cogn Disord
PY  - 2000
VL  - 11
SP  - 299
ER  - 
TY  - JOUR
LB  - 109.
AU  - Krishnan, K
AU  - Charles, HC
AU  - Doraiswamy, PM
AU  - Mintzer, J
AU  - Weisler, R
AU  - Yu, X
TI  - Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease
J2  - Am J Psychiatry
PY  - 2003
VL  - 160
SP  - 2003
EP  - 2011
ER  - 
TY  - JOUR
LB  - 110.
AU  - Mohs, RC
AU  - Doody, RS
AU  - Morris, JC
AU  - Ieni, JR
AU  - Rogers, SL
AU  - Perdomo, CA
TI  - A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
J2  - Neurology
PY  - 2001
VL  - 57
SP  - 481
ER  - 
TY  - CONF
LB  - 111.
AU  - Johannsen, P
AU  - Barcikowska, M
AU  - Dautzenberg, P
AU  - Hampel, H
AU  - Hasselbalch, S
AU  - Sakka, P
TI  - Donepezil-treated Alzheimer’s disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomised, placebo-controlled trial
T2  - The Eleventh International Congress of the International Psychogeriatric Association
CY  - Chicago, IL
DA  - 17–22 August 2003
ER  - 
TY  - JOUR
LB  - 112.
AU  - Johannsen, P
AU  - Salmon, E
AU  - Hampel, H
AU  - Xu, Y
AU  - Richardson, S
AU  - Qvitzau, S
TI  - Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease
J2  - CNS Drugs
PY  - 2006
VL  - 20
SP  - 311
EP  - 325
ER  - 
TY  - JOUR
LB  - 113.
AU  - Rogers, SL
AU  - Farlow, MR
AU  - Doody, RS
AU  - Mohs, R
AU  - Friedhoff, LT
TI  - A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease
J2  - Neurology
PY  - 1998
VL  - 50
SP  - 136
ER  - 
TY  - JOUR
LB  - 114.
AU  - Rogers, SL
AU  - Friedhoff, LT
TI  - The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial
J2  - Dementia
PY  - 1996
VL  - 7
SP  - 293
EP  - 303
ER  - 
TY  - JOUR
LB  - 115.
AU  - Seltzer, B
AU  - Zolnouni, P
AU  - Nunez, M
AU  - Goldman, R
AU  - Kumar, D
AU  - Ieni, J
TI  - Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial
J2  - Arch Neurol
PY  - 2004
VL  - 61
SP  - 1852
EP  - 1856
ER  - 
TY  - JOUR
LB  - 116.
AU  - Winblad, B
AU  - Engedal, K
AU  - Soininen, H
AU  - Verhey, F
AU  - Waldemar, G
AU  - Wimo, A
TI  - A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
J2  - Neurology
PY  - 2001
VL  - 57
SP  - 489
ER  - 
TY  - JOUR
LB  - 117.
AU  - Wimo, A
AU  - Winblad, B
AU  - Engedal, K
AU  - Soininen, H
AU  - Verhey, F
AU  - Waldemar, G
TI  - An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial
J2  - Dement Geriatr Cogn Disord
PY  - 2003
VL  - 15
SP  - 44
ER  - 
TY  - JOUR
LB  - 118.
AU  - Mazza, M
AU  - Capuano, A
AU  - Bria, P
AU  - Mazza, S
TI  - Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer’s dementia in a randomized placebo-controlled double-blind study
J2  - Eur J Neurol
PY  - 2006
VL  - 13
SP  - 981
EP  - 985
ER  - 
TY  - JOUR
LB  - 119.
AU  - dos Santos Moraes, WA
AU  - Poyares, DR
AU  - Guilleminault, C
AU  - Ramos, LR
AU  - Ferreira Bertolucci, PH
AU  - Tufik, S
TI  - The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study
J2  - Sleep
PY  - 2006
VL  - 29
SP  - 199
EP  - 205
ER  - 
TY  - JOUR
LB  - 120.
AU  - Moraes, W
AU  - Poyares, D
AU  - Sukys-Claudino, L
AU  - Guilleminault, C
AU  - Tufik, S
TI  - Donepezil improves obstructive sleep apnea in Alzheimer disease: a double-blind, placebo-controlled study
J2  - Chest
PY  - 2008
VL  - 133
SP  - 677
EP  - 683
ER  - 
TY  - JOUR
LB  - 121.
AU  - Peng, DT
AU  - Xu, XH
AU  - Wang, LN
TI  - Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease
J2  - Chin J Clin Rehabil
PY  - 2005
VL  - 9
SP  - 170
EP  - 172
ER  - 
TY  - JOUR
LB  - 122.
AU  - Winstein, CJ
AU  - Bentzen, KR
AU  - Boyd, L
AU  - Schneider, LS
TI  - Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer’s disease?
J2  - Curr Alzheimer Res
PY  - 2007
VL  - 4
SP  - 273
EP  - 276
ER  - 
TY  - JOUR
LB  - 123.
AU  - Raskind, MA
AU  - Peskind, ER
AU  - Wessel, T
AU  - Yuan, W
TI  - Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension
J2  - Neurology
PY  - 2000
VL  - 54
SP  - 2261
ER  - 
TY  - JOUR
LB  - 124.
AU  - Rockwood, K
AU  - Mintzer, J
AU  - Truyen, L
AU  - Wessel, T
AU  - Wilkinson, D
TI  - Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial
J2  - BMJ
PY  - 2001
VL  - 71
SP  - 589
ER  - 
TY  - JOUR
LB  - 125.
AU  - Tariot, PN
AU  - Solomon, PR
AU  - Morris, JC
AU  - Kershaw, P
AU  - Lilienfeld, S
AU  - Ding, C
TI  - A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group
J2  - Neurology
PY  - 2000
VL  - 54
SP  - 2269
ER  - 
TY  - JOUR
LB  - 126.
AU  - Cummings, JL
AU  - Schneider, L
AU  - Tariot, PN
AU  - Kershaw, PR
AU  - Yuan, W
TI  - Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer’s disease
J2  - Am J Psychiatry
PY  - 2004
VL  - 161
SP  - 532
EP  - 538
ER  - 
TY  - JOUR
LB  - 127.
AU  - Wilcock, GK
AU  - Lilienfeld, S
AU  - Gaens, E
TI  - Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial
J2  - BMJ
PY  - 2000
VL  - 321
SP  - 1445
ER  - 
TY  - JOUR
LB  - 128.
AU  - Wilkinson, D
AU  - Murray, J
TI  - Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer’s disease
J2  - Int J Geriatr Psychiatry
PY  - 2001
VL  - 16
SP  - 852
ER  - 
TY  - JOUR
LB  - 129.
AU  - Wilkinson, D
AU  - Lilienfeld, S
AU  - Truyen, L
TI  - Galantamine improves activities of daily living in patients with Alzheimer’s disease: a 3-month placebo-controlled study
PY  - 2000
ER  - 
TY  - JOUR
LB  - 130.
AU  - Erkinjuntti, T
AU  - Kurz, A
AU  - Gauthier, S
AU  - Bullock, R
AU  - Lilienfeld, S
AU  - Damaraju, CV
TI  - Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial
J2  - Lancet
PY  - 2002
VL  - 359
SP  - 1283
EP  - 1290
ER  - 
TY  - JOUR
LB  - 131.
AU  - Rockwood, K
AU  - Fay, S
AU  - Song, X
AU  - MacKnight, C
AU  - Gorman, M
TI  - Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: A randomized controlled trial
J2  - CMAJ
PY  - 2006
VL  - 174
SP  - 1099
EP  - 1105
ER  - 
TY  - JOUR
LB  - 132.
AU  - Feldman, HH
AU  - Van Baelen, B
AU  - Kavanagh, S
TI  - Effects of galantamine on activities of daily living in Alzheimer’s disease: evidence from six randomised double-blind placebo-controlled trials
J2  - Res Pract Alzheimers Dis
PY  - 2005
VL  - 10
SP  - 234
EP  - 238
ER  - 
TY  - JOUR
LB  - 133.
AU  - Rockwood, K
AU  - Fay, S
AU  - Jarrett, P
AU  - Asp, E
TI  - Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial
J2  - Neurology
PY  - 2007
VL  - 68
SP  - 1116
EP  - 1121
ER  - 
TY  - JOUR
LB  - 134.
AU  - Agid, Y
AU  - Dubois, B
AU  - Anand, R
AU  - Gharabawi, G
TI  - Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type
J2  - Curr Ther Res
PY  - 1998
VL  - 59
SP  - 837
EP  - 845
ER  - 
TY  - JOUR
LB  - 135.
AU  - Corey-Bloom, J
AU  - Anand, R
AU  - Veach, J
TI  - A randomized trial evaluating the efficacy and safety of ENA 713(rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease
J2  - Int J Geriatr Psychopharmacol
PY  - 1998
VL  - 1
SP  - 55
EP  - 65
ER  - 
TY  - JOUR
LB  - 136.
AU  - Forette, F
AU  - Anand, R
AU  - Gharabawi, G
TI  - A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®)
J2  - Eur J Neurol
PY  - 1999
VL  - 6
SP  - 423
EP  - 429
ER  - 
TY  - JOUR
LB  - 137.
AU  - Rosler, M
AU  - Anand, R
AU  - Cicin-Sain, A
AU  - Gauthier, S
AU  - Agid, Y
AU  - Dal-Bianco, P
TI  - Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial – Commentary: Another piece of the Alzheimer’s jigsaw
J2  - BMJ
PY  - 1999
VL  - 318
SP  - 633
ER  - 
TY  - JOUR
LB  - 138.
AU  - Feldman, HH
AU  - Lane, R
TI  - Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease
J2  - J Neurol Neurosurg Psychiatry
PY  - 2007
VL  - 78
SP  - 1056
EP  - 1063
ER  - 
TY  - JOUR
LB  - 139.
AU  - Mowla, A
AU  - Mosavinasab, M
AU  - Haghshenas, H
AU  - Haghighi, AB
TI  - Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s dementia? A double-blind, placebo-controlled clinical trial
J2  - J Clin Psychopharmacol
PY  - 2007
VL  - 27
SP  - 484
EP  - 487
ER  - 
TY  - JOUR
LB  - 140.
AU  - Winblad, B
AU  - Cummings, J
AU  - Andreasen, N
AU  - Grossberg, G
AU  - Onofrj, M
AU  - Sadowsky, C
TI  - A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease: rivastigmine patch versus capsule
J2  - Int J Geriatr Psychiatry
PY  - 2007
VL  - 22
SP  - 456
EP  - 467
ER  - 
TY  - JOUR
LB  - 141.
AU  - Tariot, PN
AU  - Farlow, MR
AU  - Grossberg, GT
AU  - Graham, SM
AU  - McDonald, S
AU  - Gergel, I
TI  - Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
J2  - JAMA
PY  - 2004
VL  - 291
SP  - 317
EP  - 324
ER  - 
TY  - JOUR
LB  - 142.
AU  - Reisberg, B
AU  - Doody, R
AU  - Stoffler, A
AU  - Schmitt, F
AU  - Ferris, S
AU  - Mobius, HJ
TI  - Memantine in moderate-to-severe Alzheimer’s disease
J2  - N Engl J Med
PY  - 2003
VL  - 348
SP  - 1333
ER  - 
TY  - JOUR
LB  - 143.
AU  - Van Dyck, CH
AU  - Tariot, PN
AU  - Meyers, B
AU  - Malca Resnick, E
TI  - A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease
J2  - Alzheimer Dis Assoc Disord
PY  - 2007
VL  - 21
SP  - 136
EP  - 143
ER  - 
TY  - JOUR
LB  - 144.
AU  - Fuschillo, C
AU  - La, PS
AU  - Campana, F
AU  - Pinto, A
AU  - De, SL
TI  - Cognitive deficits in Alzheimer’s disease: treatment with acetylcholinesterase inhibitor agents
J2  - Arch Gerontol Geriatr
PY  - 2001
VL  - 33
SP  - 151
EP  - 158
ER  - 
TY  - JOUR
LB  - 145.
AU  - Wilkinson, DG
AU  - Passmore, AP
AU  - Bullock, R
AU  - Hopker, SW
AU  - Smith, R
AU  - Potocnik, FCV
TI  - A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease
J2  - Int J Clin Pract
PY  - 2002
VL  - 56
SP  - 441
EP  - 446
ER  - 
TY  - JOUR
LB  - 146.
AU  - Jones, RW
AU  - Soininen, H
AU  - Hager, K
AU  - Aarsland, D
AU  - Passmore, P
AU  - Murthy, A
TI  - A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer’s disease
J2  - Int J Geriatr Psychiatry
PY  - 2004
VL  - 19
SP  - 58
EP  - 67
ER  - 
TY  - JOUR
LB  - 147.
AU  - Nordberg, A
AU  - Darreh-Shori, T
AU  - Peskind, E
AU  - Soininen, H
AU  - Mousavi, M
AU  - Eagle, G
TI  - Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
J2  - Curr Alzheimer Res
PY  - 2009
VL  - 6
SP  - 4
EP  - 14
ER  - 
TY  - JOUR
LB  - 148.
AU  - Bullock, R
AU  - Touchon, J
AU  - Bergman, H
AU  - Gambina, G
AU  - He, Y
AU  - Rapatz, G
TI  - Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer’s disease over a 2-year period
J2  - Curr Med Res Opin
PY  - 2005
VL  - 21
SP  - 1317
EP  - 1327
ER  - 
TY  - JOUR
LB  - 149.
AU  - Ancoli-Israel, S
AU  - Amatniek, J
AU  - Ascher, S
AU  - Sadik, K
AU  - Ramaswamy, K
TI  - Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study
J2  - Alzheimer Dis Assoc Disord
PY  - 2005
VL  - 19
SP  - 240
EP  - 245
ER  - 
TY  - JOUR
LB  - 150.
AU  - Porsteinsson, AP
AU  - Grossberg, GT
AU  - Mintzer, J
AU  - Olin, JT
TI  - Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial
J2  - Curr Alzheimer Res
PY  - 2008
VL  - 5
SP  - 83
EP  - 89
ER  - 
TY  - JOUR
LB  - 151.
AU  - Loveman, E
AU  - Green, C
AU  - Kirby, J
AU  - Takeda, A
AU  - Picot, J
AU  - Payne, E
TI  - The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease
J2  - Health Technol Assess
PY  - 2006
VL  - 10
IS  - 1
ER  - 
TY  - JOUR
LB  - 152.
AU  - Evers, S
AU  - Goossens, M
AU  - de Vet, H
AU  - van Tulder, M
AU  - Ament, A
TI  - Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria
J2  - Int J Technol Assess Health Care
PY  - 2005
VL  - 21
SP  - 240
EP  - 245
ER  - 
TY  - JOUR
LB  - 153.
AU  - Weinstein, MC
AU  - O’Brien, B
AU  - Hornberger, J
AU  - Jackson, J
AU  - Johannesson, M
AU  - McCabe, C
TI  - Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practice: modeling studies
J2  - Value Health
PY  - 2003
VL  - 6
SP  - 9
EP  - 17
ER  - 
TY  - JOUR
LB  - 154.
AU  - Green, C
TI  - Modelling disease progression in Alzheimer’s disease: a review of modelling methods used for cost-effectiveness analysis
J2  - Pharmacoeconomics
PY  - 2007
VL  - 25
SP  - 735
EP  - 750
ER  - 
TY  - JOUR
LB  - 155.
AU  - Sheehan, B
AU  - Phillips, P
AU  - Juszczak, E
AU  - Adams, J
AU  - Baldwin, A
AU  - Ballard, C
TI  - DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer’s disease – a multicentre RCT
J2  - Trials
PY  - 2009
VL  - 10
SP  - 57
ER  - 
TY  - JOUR
LB  - 156.
AU  - Jonsson, L
AU  - Wimo, A
TI  - The cost of dementia in Europe. A review of the evidence, and methodological considerations
J2  - Pharmacoeconomics
PY  - 2009
VL  - 27
SP  - 391
EP  - 403
ER  - 
TY  - JOUR
LB  - 157.
AU  - Oremus, M
TI  - Systematic review of economic evaluations of Alzheimer’s disease medications
J2  - Expert Rev Pharmacoecon Outcomes Res
PY  - 2008
VL  - 8
SP  - 273
EP  - 289
ER  - 
TY  - JOUR
LB  - 158.
AU  - Weimer, DL
AU  - Sager, MA
TI  - Early identification and treatment of Alzheimer’s disease: Social and fiscal outcomes
J2  - Alzheimers Dement
PY  - 2009
VL  - 5
SP  - 215
EP  - 226
ER  - 
TY  - JOUR
LB  - 159.
AU  - Getsios, D
AU  - Blume, S
AU  - Ishak, KJ
AU  - MacLaine, G
TI  - Cost-effectiveness of screening and treatment of Alzheimer’s disease with donepezil in the United Kingdom
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A191
ER  - 
TY  - JOUR
LB  - 160.
AU  - Feldman, H
AU  - Gauthier, S
AU  - Hecker, J
AU  - Vellas, B
AU  - Hux, M
AU  - Xu, Y
TI  - Economic evaluation of donepezil in moderate to severe Alzheimer disease
J2  - Neurology
PY  - 2004
VL  - 63
SP  - 644
EP  - 650
ER  - 
TY  - JOUR
LB  - 161.
AU  - Fuh, JL
AU  - Wang, SJ
AU  - Fuh, JL
AU  - Wang, SJ
TI  - Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer’s disease in Taiwan
J2  - Int J Geriatr Psychiatry
PY  - 2008
VL  - 23
SP  - 73
EP  - 78
ER  - 
TY  - JOUR
LB  - 162.
AU  - Getsios, D
AU  - Blume, S
AU  - Ishak, KJ
AU  - MacLaine, G
TI  - Cost-effectiveness study in patients with mild to moderately severe Alzheimer’s disease: projected benefits of donepezil in the United Kingdom
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A191
ER  - 
TY  - JOUR
LB  - 163.
AU  - Getsios, D
AU  - Blume, S
AU  - Ishak, KJ
AU  - MacLaine, G
TI  - Cost-effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation
J2  - Pharmacoeconomics
PY  - 2010
VL  - 28
SP  - 411
EP  - 427
ER  - 
TY  - JOUR
LB  - 164.
AU  - Lopez-Bastida, J
AU  - Hart, W
AU  - Garcia-Perez, L
AU  - Linertova, R
TI  - Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease
J2  - J Alzheimers Dis
PY  - 2009
VL  - 16
SP  - 399
EP  - 407
ER  - 
TY  - JOUR
LB  - 165.
AU  - Lu, S
AU  - Hill, J
AU  - Fillit, H
TI  - Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer’s disease and related dementias enrolled in a large medicare managed care plan: a case–control study
J2  - Am J Geriatr Pharmacother
PY  - 2005
VL  - 3
SP  - 92
EP  - 102
ER  - 
TY  - JOUR
LB  - 166.
AU  - Mesterton, J
AU  - By, A
AU  - Sandelin, R
AU  - Jonsson, L
TI  - Cost-effectiveness of donepezil in Alzheimer’s disease in Sweden
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A369
ER  - 
TY  - JOUR
LB  - 167.
AU  - Pattanaprateep, O
AU  - Phongchareonsuk, P
AU  - Chaikledkaew, U
TI  - The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer’s disease in Thailand private hospital
J2  - Value Health
PY  - 2005
VL  - 8
SP  - 314
EP  - 315
ER  - 
TY  - JOUR
LB  - 168.
AU  - Teipel, SJ
AU  - Ewers, M
AU  - Reisig, V
AU  - Schweikert, B
AU  - Hampel, H
AU  - Happich, M
TI  - Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease
J2  - Eur Arch Psychiatry Clin Neurosci
PY  - 2007
VL  - 257
SP  - 330
EP  - 336
ER  - 
TY  - JOUR
LB  - 169.
AU  - Feldman, H
AU  - Gauthier, S
AU  - Hecker, J
AU  - Vellas, B
AU  - Hux, M
AU  - Xu, Y
TI  - Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer’s disease
J2  - J Am Geriatr Soc
PY  - 2004
VL  - 52
SP  - 388
ER  - 
TY  - JOUR
LB  - 170.
AU  - Shah, SN
AU  - Feldman, H
AU  - Gauthier, S
AU  - Hecker, J
AU  - Vellas, B
AU  - Hux, M
TI  - Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer’s disease
J2  - Neurobiol Aging
PY  - 2004
VL  - 25
IS  - Suppl. 2
SP  - 208
ER  - 
TY  - JOUR
LB  - 171.
AU  - Feldman, H
AU  - Hux, M
AU  - Schwam, EM
TI  - Economic evaluation of donepezil in moderate to severe Alzheimer disease – reply
J2  - Neurology
PY  - 2005
VL  - 64
SP  - 1320
ER  - 
TY  - JOUR
LB  - 172.
AU  - Faltraco, F
AU  - Happich, M
AU  - Reisig, V
AU  - Teipel, SJ
AU  - Moeller, HJ
AU  - Hampel, H
TI  - Treatment of Alzheimer’s disease with cholinesterase inhibitors in Germany: a cost-effectiveness study
J2  - Neurobiol Aging
PY  - 2004
VL  - 25
IS  - Suppl. 2
SP  - 336
ER  - 
TY  - JOUR
LB  - 173.
AU  - Gauthier, S
AU  - Feldman, H
AU  - Hecker, J
AU  - Vellas, B
AU  - Ames, D
AU  - Subbiah, P
TI  - Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease
J2  - Int Psychogeriatr
PY  - 2002
VL  - 14
SP  - 389
EP  - 404
ER  - 
TY  - JOUR
LB  - 174.
AU  - Brennan, A
AU  - Nagy, B
AU  - Brandtmuller, A
AU  - Thomas, SK
AU  - Sullivan, SD
AU  - Akehurst, R
TI  - The cost-utility of exelon patch in the management of patients with moderate Alzheimer’s disease in the United Kingdom
J2  - Value Health
PY  - 2007
VL  - 10
SP  - A384
ER  - 
TY  - JOUR
LB  - 175.
AU  - Suh, GH
AU  - Jung, HY
AU  - Lee, CU
AU  - Choi, S
AU  - Korean Galantamine Study Group
AU  - Suh, GH
TI  - Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer’s disease in a Korean population: a 52-week prospective study
J2  - J Korean Med Sci
PY  - 2008
VL  - 23
SP  - 10
EP  - 17
ER  - 
TY  - JOUR
LB  - 176.
AU  - Suh, GH
TI  - Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer’s disease in Korea
J2  - Value Health
PY  - 2009
VL  - 12
IS  - Suppl. 3
SP  - 49
EP  - 54
ER  - 
TY  - JOUR
LB  - 177.
AU  - Antonanzas, F
AU  - Rive, B
AU  - Badenas, JM
AU  - Gomez-Lus, S
AU  - Guilhaume, C
TI  - Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: An adaptation in Spain
J2  - Eur J Health Econ
PY  - 2006
VL  - 7
SP  - 137
EP  - 144
ER  - 
TY  - JOUR
LB  - 178.
AU  - Gagnon, M
AU  - Rive, B
AU  - Hux, M
AU  - Guilhaume, C
TI  - Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada
J2  - Can J Psychiatry
PY  - 2007
VL  - 52
SP  - 519
EP  - 526
ER  - 
TY  - JOUR
LB  - 179.
AU  - Guilhaume, C
AU  - Rive, B
AU  - Francois, C
AU  - Livingston, G
AU  - Katona, C
TI  - External validation of the probabilistic Markov model estimating the cost effectiveness of memantine versus standard care in Alzheimer disease from a UK perspective
J2  - Value Health
PY  - 2005
VL  - 8
SP  - A128
ER  - 
TY  - JOUR
LB  - 180.
AU  - Jonsson, L
TI  - Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden
J2  - Am J Geriatr Pharmacother
PY  - 2005
VL  - 3
SP  - 77
EP  - 86
ER  - 
TY  - JOUR
LB  - 181.
AU  - Toumi, M
AU  - Lamure, M
AU  - Grishchenko, M
AU  - Cochran, J
AU  - Rive, B
TI  - Cost-effectiveness of memantine in the treatment of moderate to severe Alzheimer’s disease in Norway
J2  - Value Health
PY  - 2009
VL  - 12
SP  - A370
ER  - 
TY  - JOUR
LB  - 182.
AU  - Weycker, D
AU  - Taneja, C
AU  - Edelsberg, J
AU  - Erder, MH
AU  - Schmitt, FA
AU  - Setyawan, J
TI  - Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil
J2  - Curr Med Res Opin
PY  - 2007
VL  - 23
SP  - 1187
EP  - 1197
ER  - 
TY  - JOUR
LB  - 183.
AU  - Paradise, M
AU  - Walker, Z
AU  - Cooper, C
AU  - Blizard, R
AU  - Regan, C
AU  - Katona, C
AU  - Livingston, G
TI  - Prediction of survival in Alzheimer’s disease – the LASER-AD longitudinal study
J2  - Int J Geriatr Psychiatry
PY  - 2009
VL  - 24
SP  - 739
EP  - 747
ER  - 
TY  - JOUR
LB  - 184.
AU  - Bakchine, S
AU  - Loft, H
TI  - Memantine treatment in patients with mild to moderate Alzheimer’s disease: results from a randomised, double-blind, placebo-controlled 6-month study
J2  - J Alzheimers Dis
PY  - 2008
VL  - 13
SP  - 97
EP  - 107
ER  - 
TY  - JOUR
LB  - 185.
AU  - Peskind, ER
AU  - Potkin, SG
AU  - Pomara, N
AU  - Ott, BR
AU  - Graham, SM
AU  - Olin, JT
AU  - McDonald, S
TI  - Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial
J2  - Am J Geriatr Psychiatry
PY  - 2006
VL  - 14
SP  - 704
EP  - 715
ER  - 
TY  - BOOK
LB  - 186.
AU  - Curtis, L
TI  - Unit Costs of Health Social Care 2010
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 2010
ER  - 
TY  - JOUR
LB  - 187.
AU  - Jonsson, L
AU  - Andreasen, N
AU  - Kilander, L
AU  - Soininen, H
AU  - Waldemar, G
AU  - Nygaard, H
TI  - Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
J2  - Alzheimer Dis Assoc Disord
PY  - 2006
VL  - 20
SP  - 49
EP  - 55
ER  - 
TY  - JOUR
LB  - 188.
AU  - Macdonald, A
AU  - Cooper, B
TI  - Long-term care dementia services: an impending crisis
J2  - Age Ageing
PY  - 2007
VL  - 36
SP  - 16
EP  - 22
ER  - 
TY  - JOUR
LB  - 189.
AU  - Iglehart, D
TI  - Simulating Stable Stochastic Systems, V: comparison of ratio estimators
J2  - Naval Res Logist Quart
PY  - 1975
VL  - 22
SP  - 553
EP  - 565
ER  - 
TY  - JOUR
LB  - 190.
AU  - Feldman, H
AU  - Gauthier, S
AU  - Hecker, J
AU  - Vellas, B
AU  - Emir, B
AU  - Mastey, V
AU  - Subbiah, P
TI  - Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden
J2  - J Am Geriatr Soc
PY  - 2003
VL  - 51
SP  - 737
EP  - 744
ER  - 
TY  - ELEC
LB  - 191.
AU  - Bond, M
AU  - Rogers, G
AU  - Peters, J
AU  - Anderson, R
AU  - Hoyle, M
AU  - Miners, A
TI  - The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of TA111): a systematic review and economic model
UR  - www.nice.org.uk/guidance/index.jsp?action=folder%26o=51051
M1  - 6 December 2010
ER  - 
TY  - JOUR
LB  - 192.
AU  - Livingston, G
AU  - Katona, C
AU  - Roch, B
AU  - Guilhaume, C
AU  - Rive, B
TI  - A dependency model for patients with Alzheimer’s disease: its validation and relationship to the costs of care – the LASER-AD study
J2  - Curr Med Res Opin
PY  - 2004
VL  - 20
SP  - 1007
EP  - 1016
ER  - 
TY  - JOUR
LB  - 193.
AU  - Stern, Y
AU  - Tang, MX
AU  - Albert, MS
AU  - Brandt, J
AU  - Jacobs, DM
AU  - Bell, K
TI  - Predicting time to nursing home care and death in individuals with Alzheimer disease
J2  - JAMA
PY  - 1997
VL  - 277
SP  - 806
EP  - 812
ER  - 
TY  - JOUR
LB  - 194.
AU  - Stern, Y
AU  - Albert, SM
AU  - Sano, M
AU  - Richards, M
AU  - Miller, L
AU  - Folstein, M
TI  - Assessing patient dependence in Alzheimer’s disease
J2  - J Gerontol
PY  - 1994
VL  - 49
SP  - 216
EP  - 222
ER  - 
TY  - JOUR
LB  - 195.
AU  - Hoyle, M
AU  - Anderson, R
TI  - Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts
J2  - Med Decis Making
PY  - 2010
VL  - 30
SP  - 426
EP  - 437
ER  - 
TY  - JOUR
LB  - 196.
AU  - Wolstenholme, J
AU  - Fenn, P
AU  - Gray, A
AU  - Keene, J
AU  - Jacoby, R
AU  - Hope, T
TI  - Estimating the relationship between disease progression and cost of care in dementia
J2  - Br J Psychiatry
PY  - 2002
VL  - 181
SP  - 36
EP  - 42
ER  - 
TY  - JOUR
LB  - 197.
AU  - Livingston, G
AU  - Katona, C
AU  - Francois, C
AU  - Guilhaume, C
AU  - Cochran, J
AU  - Sapin, C
TI  - Characteristics and health status change over 6 months in people with moderately severe to severe Alzheimer’s disease in the UK
J2  - Int Psychogeriatr
PY  - 2006
VL  - 18
SP  - 527
EP  - 538
ER  - 
TY  - GEN
LB  - 198.
AU  - National Institute for Health and Clinical Excellence (NICE)
TI  - Guide to the methods of technology appraisal
CY  - London
PB  - NICE
PY  - 2008
ER  - 
TY  - JOUR
LB  - 199.
AU  - Galasko, D
AU  - Schmitt, F
AU  - Thomas, R
AU  - Jin, S
AU  - Bennett, D
AU  - Ferris, S
TI  - Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease
J2  - J Int Neuropsychol Soc
PY  - 2005
VL  - 11
SP  - 446
EP  - 453
ER  - 
TY  - BOOK
LB  - 200.
AU  - Briggs, A
AU  - Claxton, K
AU  - Sculpher, M
TI  - Decision modelling for health economic evaluation
CY  - Oxford
PB  - Oxford University Press
PY  - 2008
ER  - 
TY  - JOUR
LB  - 201.
AU  - Doraiswamy, PM
AU  - Bieber, F
AU  - Kaiser, L
AU  - Krishnan, KR
AU  - Reuning-Scherer, J
AU  - Gulanski, B
TI  - The Alzheimer’s Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer’s disease trials
J2  - Neurology
PY  - 1997
VL  - 48
SP  - 1511
EP  - 1517
ER  - 
TY  - JOUR
LB  - 202.
AU  - Miller, EA
AU  - Schneider, LS
AU  - Zbrozek, A
AU  - Rosenheck, RA
TI  - Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer’s Disease
J2  - Value Health
PY  - 2008
VL  - 11
SP  - 1120
EP  - 1130
ER  - 
TY  - JOUR
LB  - 203.
AU  - Naglie, G
AU  - Tomlinson, G
AU  - Tansey, C
AU  - Irvine, J
AU  - Ritvo, P
AU  - Black, SE
TI  - Utility-based quality of life measures in Alzheimer’s disease
J2  - Qual Life Res
PY  - 2006
VL  - 15
SP  - 631
EP  - 643
ER  - 
TY  - JOUR
LB  - 204.
AU  - Ekman, M
AU  - Berg, J
AU  - Wimo, A
AU  - Jonsson, L
AU  - McBurney, C
TI  - Health utilities in mild cognitive impairment and dementia: a population study in Sweden
J2  - Int J Geriatr Psychiatry
PY  - 2007
VL  - 22
SP  - 649
EP  - 655
ER  - 
TY  - JOUR
LB  - 205.
AU  - Wlodarczyk, JH
AU  - Brodaty, H
AU  - Hawthorne, G
AU  - Wlodarczyk, JH
AU  - Brodaty, H
AU  - Hawthorne, G
TI  - The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer’s disease
J2  - Arch Gerontol Geriatr
PY  - 2004
VL  - 39
SP  - 25
EP  - 33
ER  - 
TY  - JOUR
LB  - 206.
AU  - Andersen, CK
AU  - Wittrup-Jensen, KU
AU  - Lolk, A
AU  - Andersen, K
AU  - Kragh, S
AU  - Andersen, CK
TI  - Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia
J2  - Health Qual Life Outcomes
PY  - 2004
VL  - 2
SP  - 52
ER  - 
TY  - JOUR
LB  - 207.
AU  - Karlawish, JH
AU  - Zbrozek, A
AU  - Kinosian, B
AU  - Gregory, A
AU  - Ferguson, A
AU  - Low, DV
TI  - Caregivers’ assessments of preference-based quality of life in Alzheimer’s disease
J2  - Alzheimers Dement
PY  - 2008
VL  - 4
SP  - 203
EP  - 211
ER  - 
TY  - JOUR
LB  - 208.
AU  - Karlawish, JH
AU  - Casarett, D
AU  - Klocinski, J
AU  - Clark, CM
TI  - The relationship between caregivers’ global ratings of Alzheimer’s disease patients’ quality of life, disease severity, and the caregiving experience
J2  - J Am Geriatr Soc
PY  - 2001
VL  - 49
SP  - 1066
EP  - 1070
ER  - 
TY  - JOUR
LB  - 209.
AU  - Sands, LP
AU  - Ferreira, P
AU  - Stewart, AL
AU  - Brod, M
AU  - Yaffe, K
TI  - What explains differences between dementia patients’ and their caregivers’ ratings of patients’ quality of life?
J2  - Am J Geriatr Psychiatry
PY  - 2004
VL  - 12
SP  - 272
EP  - 280
ER  - 
TY  - JOUR
LB  - 210.
AU  - Vogel, A
AU  - Mortensen, EL
AU  - Hasselbalch, SG
AU  - Andersen, BB
AU  - Waldemar, G
TI  - Patient versus informant reported quality of life in the earliest phases of Alzheimer’s disease
J2  - Int J Geriatr Psychiatry
PY  - 2006
VL  - 21
SP  - 1132
EP  - 1138
ER  - 
TY  - JOUR
LB  - 211.
AU  - Kerner, DN
AU  - Patterson, TL
AU  - Grant, I
AU  - Kaplan, RM
TI  - Validity of the Quality of Well-Being Scale for Patients with Alzheimer’s disease
J2  - J Aging Health
PY  - 1998
VL  - 10
SP  - 44
EP  - 61
ER  - 
TY  - JOUR
LB  - 212.
AU  - Sano, M
AU  - Albert, SM
AU  - Tractenberg, RE
AU  - Schittini, M
TI  - Developing utilities: quantifying quality of life for stages of Alzheimer’s disease as measured by the clinical dementia rating
J2  - J Mental Health Aging
PY  - 1999
VL  - 5
SP  - 59
EP  - 68
ER  - 
TY  - JOUR
LB  - 213.
AU  - Neumann, PJ
AU  - Kuntz, KM
AU  - Leon, J
AU  - Araki, SS
AU  - Hermann, RC
AU  - Hsu, MA
TI  - Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers
J2  - Med Care
PY  - 1999
VL  - 37
SP  - 27
EP  - 32
ER  - 
TY  - JOUR
LB  - 214.
AU  - Huang, HL
AU  - Chang, MY
AU  - Tang, JSH
AU  - Chiu, YC
AU  - Weng, LC
TI  - Determinants of the discrepancy in patient- and caregiver-rated quality of life for persons with dementia
J2  - J Clin Nurs
PY  - 2008
VL  - 18
SP  - 3107
EP  - 3117
ER  - 
TY  - JOUR
LB  - 215.
AU  - Perneczky, R
AU  - Wagenpfeil, S
AU  - Komossa, K
AU  - Grimmer, T
AU  - Diehl, J
AU  - Kurz, A
TI  - Mapping scores onto stages: mini-mental state examination and clinical dementia rating
J2  - Am J Geriatr Psychiatry
PY  - 2006
VL  - 14
SP  - 139
EP  - 144
ER  - 
TY  - BOOK
LB  - 216.
AU  - Curtis, L
TI  - Unit Costs of Health Social Care 2009
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 2009
ER  - 
TY  - GEN
LB  - 217.
AU  - Department of Health
TI  - NHS reference costs 2008–9
CY  - London
PB  - Department of Health
PY  - 2010
ER  - 
TY  - GEN
LB  - 218.
AU  - British Medical Association and Royal Pharmaceutical Society of Great Britain
TI  - British national formulary
CY  - London
PB  - BMA and RPS
PY  - 2009
ER  - 
TY  - GEN
LB  - 219.
AU  - British Medical Association and Royal Pharmaceutical Society of Great Britain
TI  - British national formulary
CY  - London
PB  - BMA and RPS
PY  - 2010
ER  - 
TY  - BOOK
LB  - 220.
AU  - Curtis, L
TI  - Unit Costs of Health Social Care 1998
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 1998
ER  - 
TY  - BOOK
LB  - 221.
AU  - Curtis, L
TI  - Unit Costs of Health Social Care 1999
CY  - Canterbury
PB  - PSSRU, University of Kent
PY  - 1999
ER  - 
TY  - BOOK
LB  - 222.
AU  - Curtis, L
AU  - Netten, A
TI  - Unit Costs of Health Social Care 2004
EP  - Canterbury
PB  - PSSRU, University of Kent
PY  - 2004
ER  - 
TY  - JOUR
LB  - 223.
AU  - Hoyle, M
TI  - Future drug prices and cost-effectiveness analyses
J2  - Pharmacoeconomics
PY  - 2008
VL  - 26
SP  - 589
EP  - 602
ER  - 
TY  - JOUR
LB  - 224.
AU  - Rogers, G
AU  - Hoyle, M
AU  - Thompson-Coon, J
AU  - Pitt, M
AU  - Moxham, T
AU  - Liu, Z
TI  - Dasatinib and nilotinib for imatinib-resistant or intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
J2  - Health Technol Assess
PY  - 2012
ER  - 
TY  - JOUR
LB  - 225.
AU  - Thompson-Coon, J
AU  - Hoyle, M
AU  - Green, C
AU  - Liu, Z
AU  - Welch, K
AU  - Moxham, T
TI  - Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
J2  - Health Technol Assess
PY  - 2012
ER  - 
TY  - JOUR
LB  - 226.
AU  - Bond, M
AU  - Wyatt, K
AU  - Lloyd, J
AU  - Welch, K
AU  - Taylor, RS
TI  - Systematic review of the effectiveness and cost-effectiveness of weight management schemes for the under fives
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 61
ER  - 
TY  - JOUR
LB  - 227.
AU  - Bond, M
AU  - Mealing, S
AU  - Anderson, R
AU  - Elston, J
AU  - Weiner, G
AU  - Taylor, RS
TI  - The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 44
ER  - 
TY  - JOUR
LB  - 228.
AU  - Bond, M
AU  - Pitt, M
AU  - Akoh, J
AU  - Moxham, T
AU  - Hoyle, M
AU  - Anderson, R
TI  - The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 38
ER  - 
TY  - JOUR
LB  - 229.
AU  - Rogers, G
AU  - Elston, J
AU  - Garside, R
AU  - Roome, C
AU  - Taylor, RS
AU  - Younger, P
TI  - The harmful health effects of recreational ecstasy: a systematic review of observational evidence
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 6
ER  - 
TY  - JOUR
LB  - 230.
AU  - Taylor, RS
AU  - Elston, J
TI  - The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK health technology assessment reports
J2  - Health Technol Assess
PY  - 2009
VL  - 13
IS  - 8
ER  - 
TY  - JOUR
LB  - 231.
AU  - Main, C
AU  - Shepherd, J
AU  - Anderson, R
AU  - Rogers, G
AU  - Thompson-Coon, J
AU  - Liu, Z
TI  - Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years
J2  - Health Technol Assess
PY  - 2008
VL  - 12
IS  - 20
ER  - 
TY  - JOUR
LB  - 232.
AU  - Fox, M
AU  - Mealing, S
AU  - Anderson, R
AU  - Dean, J
AU  - Stein, K
AU  - Price, A
TI  - The Clinical Effectiveness and Cost-effectiveness of Cardiac Resynchronisation (Biventricular Pacing) for Heart Failure: a systematic review and economic model
J2  - Health Technol Assess
PY  - 2007
VL  - 11
IS  - 47
ER  - 
TY  - JOUR
LB  - 233.
AU  - Pearson, M
AU  - Garside, R
AU  - Moxham, T
AU  - Anderson, R
TI  - Preventing unintentional injuries to children in the home: a systematic review of the effectiveness of programmes supplying and/or installing home safety equipment
J2  - Health Prom Int
PY  - 2011
VL  - 26
SP  - 376
EP  - 392
ER  - 
TY  - JOUR
LB  - 234.
AU  - Mecocci, P
AU  - Bladstrom, A
AU  - Stender, K
TI  - Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
J2  - Int J Geriatr Psychiatry
PY  - 2009
VL  - 24
SP  - 532
EP  - 538
ER  - 
TY  - JOUR
LB  - 235.
AU  - Gauthier, S
AU  - Loft, H
AU  - Cummings, J
TI  - Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis
J2  - Int J Geriatr Psychiatry
PY  - 2008
VL  - 23
SP  - 537
EP  - 545
ER  - 
TY  - JOUR
LB  - 236.
AU  - Wilcock, GK
AU  - Ballard, CG
AU  - Cooper, JA
AU  - Loft, H
TI  - Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: A pooled analysis of 3 studies
J2  - J Clin Psychiatry
PY  - 2008
VL  - 69
SP  - 341
EP  - 348
ER  - 
TY  - JOUR
LB  - 237.
AU  - Farlow, MR
AU  - Graham, SM
AU  - Alva, G
TI  - Memantine for the treatment of Alzheimer’s disease
J2  - Drug Safety
PY  - 2008
VL  - 31
SP  - 577
EP  - 585
ER  - 
TY  - JOUR
LB  - 238.
AU  - Quentin, W
AU  - Riedel-Heller, S
AU  - Luppa, M
AU  - Rudolph, A
AU  - König, H-H
TI  - Cost-of illness studies of dementia: a systematic review focusing on stage dependency of costs
J2  - Acta Psychiatr Scand
PY  - 2010
VL  - 121
SP  - 243
EP  - 259
ER  - 
TY  - JOUR
LB  - 239.
AU  - Lowin, A
AU  - Knapp, M
AU  - McCrone, P
TI  - Alzheimer’s disease in the UK: comparative evidence on cost of illness and volume of health services research funding
J2  - Int J Geriatr Psychiatry
PY  - 2001
VL  - 16
SP  - 1143
EP  - 1148
ER  - 
TY  - JOUR
LB  - 240.
AU  - Souêtre, E
AU  - Thwaites, R
AU  - Yeardley, H
TI  - Economic impact of Alzheimer’s disease in the United Kingdom: Cost of care and disease deverity for non-institutionalised patients with Alzheimer’s disease
J2  - Br J Psychiatry
PY  - 1999
VL  - 174
SP  - 51
EP  - 55
ER  - 
TY  - GEN
LB  - 241.
AU  - Parliamentary Office of Science and Technology (POST)
TI  - Alzheimer’s & dementia
CY  - London
PB  - Houses of Parliament
PY  - 2007
ER  - 
TY  - JOUR
LB  - 242.
AU  - Kavanagh, S
AU  - Knapp, M
TI  - Costs and cognitive disability: modelling the underlying associations
J2  - Br J Psychiatry
PY  - 2002
VL  - 180
SP  - 120
EP  - 125
ER  - 
TY  - RPRT
LB  - 243.
AU  - Martin, J
AU  - Meltzer, H
AU  - Elliot, D
TI  - The Prevalence of Disability Among Adults: OPCS Surveys of Disability in Great Britain Report I
CY  - London
PB  - HMSO
PY  - 1988
ER  - 
TY  - JOUR
LB  - 244.
AU  - Mendiondo, MS
AU  - Ashford, JW
AU  - Kryscio, RJ
AU  - Schmitt, FA
TI  - Modelling mini mental state examination changes in Alzheimer’s disease
J2  - Stat Med
PY  - 2000
VL  - 19
SP  - 1607
EP  - 1616
ER  -